CureSound

About

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is CureSound's primary product?

CureSound's primary product is the BRH-A2, a noninvasive, FDA-cleared portable medical device designed to heal chronic ulcers, reduce lesion size, lessen wound pain, and accelerate tissue regrowth using therapeutic ultrasound and electrostimulation.

When was CureSound founded?

CureSound was founded in September 2010.

What significant recognition did CureSound receive in 2013?

In June 2013, CureSound won the 8200 Israeli Startup Competition.

What was a key regulatory achievement for CureSound in 2017?

In November 2017, CureSound's BRH-A2 device received FDA clearance to treat serious wounds using electric fields and ultrasound.

Has CureSound secured any patents for its technology?

Yes, in November 2016, CureSound (then BRH Medical) received patents in both the USA and China for its innovative wound healing therapy.

What is the total amount of funding CureSound has raised?

CureSound has raised a total of $600,000 in funding. For full financing history, refer to startupim.

How many employees does CureSound currently have?

CureSound currently has 6 employees.

In which geographic markets does CureSound operate?

CureSound operates in the geographic markets of South Africa, Global, and India.

What are the former names of CureSound?

CureSound was formerly known as BRH Medical.

Sectors & technology

Highlights

Tags